Bridget Silverman has been covering FDA for the Pink Sheet since David Kessler was commissioner, with a focus on the US drug review and approval process. She oversees the FDA Performance Tracker suite of interactive charts and the Drug Review Profile series of deep dives into FDA review decisions.
Bridget is especially interested in how regulatory reforms and policy initiatives affect clinical trial design and R&D strategy. She covered the commercial and financial beats for the Pink Sheet before focusing on drug development as an editor on Pharmaceutical Approvals Monthly and the NDA Pipeline, where she helped to develop database products that inform our current regulatory tracking features. In her down time, Bridget reads mystery novels and keeps track of her family and three dogs.
